Liver ischaemia-reperfusion injury: a new understanding of the role of innate immunity

In this Review, Kupiec-Weglinski and colleagues describe the roles of macrophages, neutrophils, and platelets in liver ischaemia-reperfusion injury (LIRI) and discuss potential therapeutic strategies for treating LIRI in transplant recipients. Liver ischaemia-reperfusion injury (LIRI), a local sterile inflammatory response driven by innate immunity, is one of the primary causes of early organ dysfunction and failure after liver transplantation. Cellular damage resulting from LIRI is an important risk factor not only for graft dysfunction but also for acute and even chronic rejection and exacerbates the shortage of donor organs for life-saving liver transplantation. Hepatocytes, liver sinusoidal endothelial cells and Kupffer cells, along with extrahepatic monocyte-derived macrophages, neutrophils and platelets, are all involved in LIRI. However, the mechanisms underlying the responses of these cells in the acute phase of LIRI and how these responses are orchestrated to control and resolve inflammation and achieve homeostatic tissue repair are not well understood. Technological advances allow the tracking of cells to better appreciate the role of hepatic macrophages and platelets (such as their origin and immunomodulatory and tissue-remodelling functions) and hepatic neutrophils (such as their selective recruitment, anti-inflammatory and tissue-repairing functions, and formation of extracellular traps and reverse migration) in LIRI. In this Review, we summarize the role of macrophages, platelets and neutrophils in LIRI, highlight unanswered questions, and discuss prospects for innovative therapeutic regimens against LIRI in transplant recipients.

Automated summary

The authors of this Review examine the roles of macrophages, platelets, and neutrophils in liver ischaemia-reperfusion injury (LIRI), discussing potential therapeutic strategies for treating LIRI in transplant recipients. They highlight the unanswered questions in understanding the mechanisms underlying the responses of these cells in the acute phase of LIRI, and discuss prospects for innovative therapeutic regimens against LIRI in transplant recipients.